Platform Specialty listed on New York Stock Exchange

Platform's ordinary shares and warrants, which are admitted to trading on the London Stock Exchange, were suspended from trading on the London Stock Exchange on October 10, 2013 when the Company announced its intention to acquire MacDermid, Incorporated. 

Promptly following the Listing Date, Platform will request for the listing of its ordinary shares and warrants to be cancelled from the Official List of the FCA and for the admission to trading of its securities to be cancelled from the Main Market of the London Stock Exchange.

Dan Leever, Platform's CEO said, "Platform's key mission is to create value for our shareholders by building a portfolio of market-leading specialty chemicals businesses. We believe that our listing on the New York Stock Exchange furthers this objective by elevating our profile on a global scale, enhancing liquidity and visibility, and increasing the accessibility of our shares."

"We are delighted that Platform has chosen to transfer its listing to the New York Stock Exchange and we look forward to embarking on this long-term partnership with the company and its shareholders," said Scott Cutler, Executive Vice President and Head of Global Listings of NYSE Euronext. "As Platform works towards its long-term vision of being a leading global specialty chemicals company, our unique services, tools and intelligence will help the company achieve its capital markets goals."

Prior to the domestication, most of the Company's ordinary shares and all of the Company's warrants were held as depositary interests in CREST in the name of a CREST nominee.  In connection with the domestication and listing on the NYSE, these CREST positions will be transferred to the nominee's CREST participant account at the Depository Trust Company ("DTC") on behalf of each beneficial holder.

Platform Specialty Products